• Evénements
  • Webinar
    • Bioprocessing Solutions
      • A novel cell lysis solution with advantageous use characteristics for rAAV manufacturing that can lead to greater downstream recovery by minimizing upstream loss
      • Viral Clearance breakthrough: Enhancing efficacy and protein stability with a regulatory compliant, novel detergent
      • Detergent-based viral inactivation: a case study demonstrating enhanced monoclonal antibody purification
      • Advancing next gen biologic manufacturing by implementing continuous downstream processing platform
      • Adopting novel technologies to improve monoclonal antibody processes
      • Novel approach to purification and viral inactivation of new class of mAbs
      • Risk mitigation and process debottlenecking in continuous biomanufacturing
      • Increased Downstream Efficiency of mAbs through use of Novel Purification Resin and Additives
      • Efficient raw material management for improving bioprocess throughput and flexibility
      • A Changing Landscape for Biopharma
      • Use of a Novel Cell Lysis Buffer for Protection of AAVs and Enhancing Manufacturing Efficiency
      • Understanding monoclonal antibody aggregate behaviour impacting chromatographic process efficiency
      • Improved antibody purification process through use of additives
      • Novel Purification Technologies and Approaches to Maximize Speed, Efficiency and Process Optimization
      • Solutions to optimize biopharma downstream processing
      • Solutions to manage complexity in global single-use supply chain for vaccines manufacturing
      • Process debottlenecking in buffer and media prep using enhanced raw material release/delivery strategies
      • Downstream Process Intensification with Novel Chromatography Resins for Enhanced Monoclonal Antibody Purification
      • Digitalizing biopharma
      • Understanding the critical roles of cGMP chemicals and single-use technologies in cell & gene therapy manufacturing
      • Novel Single-use Solutions for Cell & Gene Therapy Manufacturing
      • Innovative direct dispense technology to ensure in-time delivery and release during continuous biomanufacturing
      • Designing Novel Fluid Sampling Systems for GMP Operations
      • Faster, better, together: Biopharma collaboration trends in the pandemic, and the future of medicine
      • A collaborative ecosystem: Accelerating the commercial manufacturing of novel vaccines and other therapeutics
      • Advancing Adeno-Associated Virus (AAV) Characterization: High-Resolution Techniques for Gene Therapy Applications
    • Chromatography
    • Equipment & instruments
    • Chemicals
    • Quality Control
    • Safety
    • Life Science
    • Controlled Environment

Many gene therapies and viral vaccines rely on a high dose of recombinant adeno-associated virus (rAAV) to deliver therapeutic DNA to patient cells, which may be challenging. Improving titer during the upstream process is important but recovering the titer during the harvest process is critical. Recovery of assembled rAAV particles can be challenging as their cytoplasmic localization requires release through cell lysis and separation from resulting cellular debris. Chemical lysis is the industry favored method of lysis to retrieve rAAV due to its scalability as well as other factors; however, variable recovery and need for environmental regulatory compliance has led to continuous development and testing of chemical solutions. In this presentation, we will demonstrate the benefits of using a novel cell lysis solution which can rapidly rupture cell membranes across a wide range of operating conditions, is compatible with traditional DNA removal agents and also provides preferential yield and titer of rAAV. The features of this cell lysis agent, along with ease-of-use qualities such as relatively low viscosity and room temperature stability at storage conditions, make it the optimal solution to improve the overall viral vector manufacturing process by providing robust and efficient cell lysis that may allow for high titer rAAV recovery.

This presentation was given at BPI Europe, April 12, 2024.

Presented by:

Joe Gallagher Technical Applications Manager For over 10 years, Joe has been dedicated to supporting Avantor’s life science customers find custom and off the shelf solutions, specifically in the genomics and cardiac development biology. His technical expertise and knowledge in emerging markets has made him successful with cell and gene therapies as new modalities come to market, while navigating the everchanging regulatory landscape. Joe graduated with a PhD in molecular microbiology from the University of Galway, followed by post-doctorates from Cardiff and Bristol Universities in the areas of genomics and cardiac developmental biology.